Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CNS Pharmaceuticals, Inc.CNSP · Entity 8048 | Director | April 08, 2024 | April 11, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CNS Pharmaceuticals, Inc.
Report date April 08, 2024 · Filed April 11, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $0.26 · Expires 2034-04-08 | Direct | 129,594 |
Reported balance
After 2024-04-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-04-08 · Grant · Acquired 17,500 · Balance 129,594 F2: The awards were issued in connection with the reporting person's Board of Director services to the Company. F1: The awards set forth in this table vest on the earlier of the one-year anniversary of the date of issuance or the date of the 2025 annual meeting, subject to the grantee's continued service to the Company on the vesting date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 147,094 |
Reported balance
After 2024-04-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-04-08 · Grant · Acquired 17,500 · Balance 147,094 F3: Each restricted stock unit represents a contingent right to receive one share of the Company common stock. F2: The awards were issued in connection with the reporting person's Board of Director services to the Company. F1: The awards set forth in this table vest on the earlier of the one-year anniversary of the date of issuance or the date of the 2025 annual meeting, subject to the grantee's continued service to the Company on the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The awards set forth in this table vest on the earlier of the one-year anniversary of the date of issuance or the date of the 2025 annual meeting, subject to the grantee's continued service to the Company on the vesting date.
F2: The awards were issued in connection with the reporting person's Board of Director services to the Company.
F3: Each restricted stock unit represents a contingent right to receive one share of the Company common stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 08, 2024 Filed Apr 11, 2024 01:52 UTC | CNS Pharmaceuticals, Inc. CNSP · Entity 8048 | GrantRestricted Stock Units · Derivative | 17,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001683168-24-002287 · ownership.xml · derivative · entry 2 Evans Carl Anthony · CIK 0001792582 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 147,094 Underlying: Common Stock · 17,500 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company common stock. F2 · price: The awards were issued in connection with the reporting person's Board of Director services to the Company. F1 · derivative.exercise_date: The awards set forth in this table vest on the earlier of the one-year anniversary of the date of issuance or the date of the 2025 annual meeting, subject to the grantee's continued service to the Company on the vesting date. F1 · derivative.expiration_date: The awards set forth in this table vest on the earlier of the one-year anniversary of the date of issuance or the date of the 2025 annual meeting, subject to the grantee's continued service to the Company on the vesting date. Read SEC document |
| April 08, 2024 Filed Apr 11, 2024 01:52 UTC | CNS Pharmaceuticals, Inc. CNSP · Entity 8048 | GrantOption to purchase common stock · Derivative | 17,500 | Not disclosed Strike: $0.26 | Not disclosed |
DisclosureSEC source: 0001683168-24-002287 · ownership.xml · derivative · entry 1 Evans Carl Anthony · CIK 0001792582 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 129,594 Underlying: Common Stock · 17,500 shares Expires 2034-04-08 F2 · price: The awards were issued in connection with the reporting person's Board of Director services to the Company. F1 · derivative.exercise_date: The awards set forth in this table vest on the earlier of the one-year anniversary of the date of issuance or the date of the 2025 annual meeting, subject to the grantee's continued service to the Company on the vesting date. Read SEC document |
| February 01, 2024 Filed Feb 6, 2024 15:27 UTC | CNS Pharmaceuticals, Inc. CNSP · Entity 8048 | GrantSeries B Warrant to purchase common stock · Derivative | 33,333 | Not disclosed Strike: $0.30 | Not disclosed |
DisclosureSEC source: 0001683168-24-000707 · ownership.xml · derivative · entry 3 Evans Carl Anthony · CIK 0001792582 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,094 Underlying: Common Stock · 33,333 shares Expires 2025-10-01 F1 · price: The common stock, Series A warrants and Series B warrants were acquired by the reporting person in a public offering conducted by the Company that was closed on February 1, 2024. Read SEC document |
| February 01, 2024 Filed Feb 6, 2024 15:27 UTC | CNS Pharmaceuticals, Inc. CNSP · Entity 8048 | GrantSeries A Warrant to purchase common stock · Derivative | 33,333 | Not disclosed Strike: $0.30 | Not disclosed |
DisclosureSEC source: 0001683168-24-000707 · ownership.xml · derivative · entry 2 Evans Carl Anthony · CIK 0001792582 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,761 Underlying: Common Stock · 33,333 shares Expires 2029-02-01 F1 · price: The common stock, Series A warrants and Series B warrants were acquired by the reporting person in a public offering conducted by the Company that was closed on February 1, 2024. Read SEC document |
| February 01, 2024 Filed Feb 6, 2024 15:27 UTC | CNS Pharmaceuticals, Inc. CNSP · Entity 8048 | PurchaseCommon stock | 33,333 | $0.30 | $9,999.90 |
DisclosureSEC source: 0001683168-24-000707 · ownership.xml · nonDerivative · entry 1 Evans Carl Anthony · CIK 0001792582 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,458 F1 · price: The common stock, Series A warrants and Series B warrants were acquired by the reporting person in a public offering conducted by the Company that was closed on February 1, 2024. Read SEC document |
| September 21, 2023 Filed Sep 25, 2023 22:24 UTC | CNS Pharmaceuticals, Inc. CNSP · Entity 8048 | GrantOption to purchase common stock · Derivative | 68,961 | Not disclosed Strike: $1.09 | Not disclosed |
DisclosureSEC source: 0001683168-23-006682 · ownership.xml · derivative · entry 1 Evans Carl Anthony · CIK 0001792582 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,914 Underlying: Common Stock · 68,961 shares Expires 2033-09-22 F2 · price: The stock options were issued in connection with the reporting person's Board of Director services to the Company. F1 · derivative.exercise_date: The stock options set forth in this table vest on the earlier of the one-year anniversary of the date of issuance or the date of the 2024 annual meeting, subject to the grantee's continued service to the Company on the vesting date. Read SEC document |
| September 21, 2023 Filed Oct 12, 2023 22:01 UTC Amendment | CNS Pharmaceuticals, Inc. CNSP · Entity 8048 | GrantOption to purchase common stock · Derivative | 39,475 | Not disclosed Strike: $1.09 | Not disclosed |
DisclosureSEC source: 0001683168-23-007110 · ownership.xml · derivative · entry 1 Evans Carl Anthony · CIK 0001792582 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,428 Underlying: Common Stock · 39,475 shares Expires 2033-09-22 F2 · price: The stock options were issued in connection with the reporting person's Board of Director services to the Company. F1 · derivative.exercise_date: The stock options set forth in this table vest on the earlier of the one-year anniversary of the date of issuance or the date of the 2024 annual meeting, subject to the grantee's continued service to the Company on the vesting date. Read SEC document |
| March 08, 2022 Filed Mar 9, 2022 19:34 UTC | CNS Pharmaceuticals, Inc. CNSP · Entity 8048 | GrantCommon Stock | 3,750 | $0.27 | $1,005.00 |
DisclosureSEC source: 0001683168-22-001545 · ownership.xml · nonDerivative · entry 1 Evans Carl Anthony · CIK 0001792582 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,750 Read SEC document |
| July 15, 2021 Filed Jul 16, 2021 21:00 UTC | CNS Pharmaceuticals, Inc. CNSP · Entity 8048 | GrantOption to purchase common stock · Derivative | 32,000 | Not disclosed Strike: $1.80 | Not disclosed |
DisclosureSEC source: 0001683168-21-002998 · ownership.xml · derivative · entry 1 Evans Carl Anthony · CIK 0001792582 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,559 Underlying: Common Stock · 32,000 shares Expires 2031-07-15 F2 · price: The stock options were issued in connection with the reporting person's Board of Director services to the Company. F1 · derivative.exercise_date: The stock options set forth in this table vest on the earlier of the one-year anniversary of the date hereof or the date of the 2022 annual meeting, subject to the grantee's continued service to the Company on the vesting date. Read SEC document |
| June 12, 2020 Filed Jun 16, 2020 21:23 UTC | CNS Pharmaceuticals, Inc. CNSP · Entity 8048 | GrantOption to purchase common stock · Derivative | 46,559 | Not disclosed Strike: $2.47 | Not disclosed |
DisclosureSEC source: 0001683168-20-001966 · ownership.xml · derivative · entry 1 Evans Carl Anthony · CIK 0001792582 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,559 Underlying: Common Stock · 46,559 shares Expires 2030-06-12 F2 · price: The stock options were issued in connection with the reporting person's Board of Director services to the Company. F1 · derivative.exercise_date: The stock options set forth in this table vest on the earlier of the one-year anniversary of the issuance date or the date of the 2021 annual meeting, subject to the grantee's continued service to the Company on the vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.